U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

BusinesswireNov 7 08:15 ET

CEL-SCI, FDA Agree on Patient Selection Approach for Multikine Study

TipRanksNov 7 09:25 ET

CEL-SCI Files to Sell 1M Shares of Common Stock for Holders

TipRanksOct 25 17:20 ET

CEL-SCI Announces The Potential Impact On The Clinical Development Of Its Immunotherapy Multikine Resulting From A Recent U.S. FDA Oncologic Drugs Advisory Committee Meeting; Multikine Has Shown Survival Benefit And Favorable Safety Profile In A...

BenzingaOct 22 09:26 ET

CEL-SCI Announces Potential Impact on Multikine Following FDA ODAC Meeting

TipRanksOct 22 09:25 ET

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

BusinesswireOct 22 09:15 ET